Bill Anderson/LinkedIn
Nov 26, 2025, 11:37
Bill Anderson on Secondary Stroke Prevention: This Week, We’ve Reached a Significant Milestone
Bill Anderson, CEO at Bayer, shared on LinkedIn:
”Those numbers tell the story: stroke is devastating.
For patients. For families.
And after surviving, the risk of another stroke is even higher.
This week, we’ve reached a significant milestone with positive topline results from our international Phase III study in secondary stroke prevention.
Our teams worked hard to get here.
Thank you, Team Bayer, for pushing to help people who’ve already been through so much.
We’re making progress—and there’s more to do.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch